J.P. Morgan
Novo Nordiskās Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
Anika Sharma
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...